Rznomics Connects Lilly Gateway Labs in San Diego to Boost RNA Therapeutics

On August 24, 2026, the South Korean clinical-stage biotechnology company Rznomics has entered into a joint partnership with Lilly Gateway Labs, which is part of Lilly Catalyze360 in San Diego, reinforcing its corporation with Eli Lilly and increasing its involvement in the United States biotechnology infrastructure. This strategy fuels opportunities for engagement and advancement in RNA-based gene therapies through strategic collaboration and specialized R&D personnel in the United States. Rznomics intends to speed up the process of discovering and developing clinical infrastructure and candidates by making use of its database containing over 200 disease targets. 

This partnership accentuates rising interest in RNA technology and may assist Rznomics in converting its proprietary trans-splicing ribozyme platform into well-curable therapies for a number of different diseases. The step comes after Rznomics reached an agreement in 2025 with Lilly for research collaboration and licensing in connection with the development of a novel RNA-editing therapeutic solution. Lily Gateway Labs enables opportunities in the biotechnology and pharmaceutical sector to access laboratory facilities and scientific resources by promoting interaction with Lilly’s scientists and executives.

Impact on the RNA Therapy Clinical Trials Industry

The global RNA therapy clinical trials market size was estimated at USD 2.82 billion in 2024 and is predicted to increase from USD 2.93 billion in 2025 to approximately USD 4.11 billion by 2034, expanding at a CAGR of 3.84% from 2025 to 2035.

According to Precedence Research, foster by the growing prevalence of genetics that align with Rznomics, is entering into a partnership with Lilly Gateway Labs. This initiative may help to build on the current momentum in the RNA therapy clinical trials sector by providing an up-and-coming company with access to a highly advanced research environment and pharmaceutical know-how. Its proprietary trans-splicing ribozyme technology is intended to allow for targeted RNA editing and create vital possibilities in a number of different areas of gene therapy.

The partnership shows that large pharmaceutical and healthcare firms are becoming highly involved with specialized RNA platforms by moving away from relying entirely on their own in-house research. By gaining access to laboratory facilities, the chance for scientific collaboration and industrial connections, and reduced development time, and the process of moving discoveries into clinical programs for better improvement. Additionally, it led to more collaborations, more licensing agreements, and greater investment in RNA technologies in the area of next-generation genetic medicines, promoting a competitive edge.

Impact on the Biotechnology Industry

The global biotechnology market size is accounted at USD 1.77 trillion in 2025 and predicted to increase from USD 2.02 trillion in 2026 to approximately USD 6.34 trillion by 2035, representing a CAGR of 13.61% from 2026 to 2035.

According to Precedence Research, the integration of advanced technology in drug discovery and the demand for personalized medicine. Rznomics moves into Lilly Gateway Labs and integrates with the innovation hub, supporting new companies to overcome problems relating to commercialization. This initiative promotes hiring U.S.-based scientists and building up clinical capabilities for contributing to international expansion. Rznomics can work within a well-developed biotechnology framework by using specialized resources and industrial support. 

The progress might prompt other Asian biotechnology companies to set up strategic U.S. bases with large pharmaceutical companies. In the end, these arrangements promote technology transfer, speed up cross-border corporation and create high opportunities for emerging and startup biotechnology companies to transform complex therapeutic platforms into specialized clinical development.

Impact on the Pharmaceutical Industry

The global pharmaceutical market size is calculated at USD 1.77 trillion in 2025 and is predicted to exceed USD 3.20 trillion by 2035, with a CAGR of 6.10% from 2026 to 2035. 

According to Precedence Research, trend towards partnership-driven pharmaceutical innovation, in which large drug companies combine their own capabilities with specialized biotechnology platforms. For the pharmaceutical sector, Rznomics' involvement in Lilly Gateway Labs underlines the strategic value of external innovation for developing future drug pipelines. Lilly acquires greater exposure to an emerging RNA platform and to a biotechnology team which is working on candidates covering a wide range of clinical targets.

Adoption should Rznomics achieve good preclinical and clinical results through its collaboration with Lilly could then serve as an example of how pharmaceutical firms identify and bring forward promising RNA technologies via ecosystem-based innovation. There is the possibility that this arrangement might lead to research relationships, licensing deals and RNA therapeutic development programmes. 

Expert Opinion

From an expert point of view, Rznomic’s involvement with Lilly Gateway labs is strategically meaningful due to its relationship with a simple licensing agreement and towards higher integration with Lilly’s innovation ecosystem. For Rznomics, the main advantage is access to aceess of scientific expertise, genomics infrastructure, and U.S. oriented talent.  Lilly acquires superior insights into a potentially distinct RNA-editing technology by providing emerging therapeutic opportunities. 

This initiative will help to speed up development of its RNA platform and diversified expansion. The company has a database of over 200 disease targets, which shows broad coverage of targets by offering safety, efficiency, and the feasibility of advancement. If the execution is successful, this collaboration may enhance Rznomic’s reputation on a global scale in the field of RNA therapeutics.